Is Idorsia Ltd (IDRSF) a Buy, Sell, or Hold?
OTC : IDRSF
Idorsia Ltd — News
$7.9 USD
$0.95 (13.67%)
- Volume
- 9.74K
- Average Volume
- 2.54K
- Market Capitalization
- $2.01B
- P/E Ratio
- -4.97
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $8.19
- Year Low
- $3.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.58
| Source | Headline |
|---|---|
|
Idorsia Ltd (IDRSF) Q2 2026 Earnings Call Transcript
Idorsia Ltd (IDRSF) Q2 2026 Earnings Call Transcript seekingalpha.com - 2026-07-30 18:03:25 |
|
Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon
Ad hoc announcement pursuant to Art. 53 LR Senior secured term loan of up to CHF 250 million with a 5‑year maturity at a fixed 7% interest rate First tranche will fully refinance the existing New Money Facility, maturing in May 2027 Eliminates near‑term debt maturities and strengthens balance sheet and liquidity profile Additional tranches available to fund targeted initiatives accelerating growth and long‑term value creation Allschwil, Switzerland – June 9, 2026 Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today announced that it has entered into a senior secured term loan agreement of up to CHF 250 million with investment funds managed by Pharmakon Advisors, LP. globenewswire.com - 2026-06-09 01:00:00 |
|
Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology
Allschwil, Switzerland – June 1, 2026 Idorsia Ltd (SIX: IDIA) today announced additional positive clinical results for IDOR-1134-2831, its vaccine targeting Clostridioides difficile (C. difficile) in a Phase 1 clinical pharmacology trial. The glycan target of this vaccine is present on both bacteria and spores – the transmissible form of the pathogen responsible for spreading infection – of the most clinically relevant C. difficile strains, including hypervirulent variants. Following initial results in June 2025, which provided the first clinical validation for Idorsia's synthetic glycan vaccine technology, the company advanced the program with a higher-dose cohort. globenewswire.com - 2026-06-01 01:05:00 |
|
New analysis of Idorsia's aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
Allschwil, Switzerland – June 01, 2026 Idorsia Ltd (SIX: IDIA) announces new analyses from the Phase 3 PRECISION study demonstrating that aprocitentan, Idorsia's dual endothelin receptor antagonist, significantly reduces albuminuria and improves albuminuria risk categories in patients with resistant hypertension. The data were presented by Prof. Markus Schlaich at the 35th Congress of the European Society of Hypertension (ESH). globenewswire.com - 2026-06-01 01:00:00 |
